Merck, Inc.
🇵🇭Philippines
Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: MK0974 tablet
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00966030
Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00963573
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Phase 1
Terminated
- Conditions
- Advanced Solid TumorsBreast Cancer
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00963547
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00961857
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00961480
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
Phase 3
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: ER niacin (+) laropiprant (ERN/LRPT)Drug: Placebo to ERN/LRPTDrug: Extended-release niacin (ERN)
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1152
- Registration Number
- NCT00961636
A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)
Phase 2
Terminated
- Conditions
- Osteoporosis
- Interventions
- Drug: MK-5442Drug: PlaceboDietary Supplement: Vitamin D3Dietary Supplement: Calcium carbonate
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 383
- Registration Number
- NCT00960934
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Phase 1
Terminated
- Conditions
- Bone CancerNeoplasmsSolid TumorsNeuroblastomaKidney Tumor
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT00960063
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
Phase 2
Completed
- Conditions
- HCV InfectionHIV InfectionsHepatitis C
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT00959699
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
Phase 1
Completed
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT00959582
© Copyright 2025. All Rights Reserved by MedPath